Blog

Angela Lamarca: We MUST validate innovate biomarkers in clinical trials

Photo from Angela Lamarca/X

Jul 4, 2024, 12:15

Angela Lamarca: We MUST validate innovate biomarkers in clinical trials

Angela Lamarca, HPB and NET Medical Oncologist at Jimenez Diaz Foundation, shared a post on X:

“Last session of the day on Precision Medicine in European Network for the Study of Cholangiocarcinoma (ENS-CCA), Precision-BTC-Network joint meeting in Krakow.

surgical candidates
neoadjuvant
chemoresistance?
markers for IO
new markers- circRNAs

We MUST validate innovate biomarkers in clinical trials.”

Source: Angela Lamarca/X

Angela Lamarca biomarkers cancer Chemoresistance cholangiocarcinoma circRNAs clinical trials ENS-CCA European Network for the Study of Cholangiocarcinoma HPB Oncologist immunotherapy Jimenez Diaz Foundation neoadjuvant therapy NET Oncologist OncoDaily Oncology Precision Medicine Precision-BTC-Network

Oncologist Near Me - Vivek Subbiah: Pionner of Precision Oncology

Monica Bertagnolli is ending her tenure as NIH director

NEW PAPER ALERT: Efficacy of CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2- Advanced Breast Cancer by PAM50 Subtype: SOLTI-1801 CDK-PREDICT Results

Oncologist Near Me – Fabrice André: Leading Expert in Breast Cancer

Funding Impactful Cancer Research That Might Otherwise Go Unsupported: Ryan Schoenfeld on the Secret Behind Mark Foundation’s Success